Enantioselective hydrogenation of intermediates in the synthesis of tipranavir

US7002017B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Franz D. Klingler · Griesheim, DE
• Michael L. Steigerwald · Bound Brook, US
• Richard Ehlenz · Bad Kreuznach, DE

Key dates

• Filing date: Mar 10, 2004
• Grant date: Feb 21, 2006
• Expiry date: Mar 10, 2024

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D309/32
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to a process for preparing the compounds of general formula I by enantioselective hydrogenation of the compounds of formula II in the presence of special hydrogenation catalysts. The invention is characterised by high enantioselectivity, providing easy access to a category of important pharmaceutical compositions, i.e. intermediates for the synthesis of tipranavir.